Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > New Press Release - Ventripoint Updates Submission to U.S. Food and Drug Administration for its Next Generation, AI-powered Heart-scanning Technology
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by jopatcloon Jan 23, 2025 7:45am
19 Views
Post# 36416589

RE:RE:New Press Release - Ventripoint Updates Submission to U.S. Food and Drug Administration for its Next Generation, AI-powered Heart-scanning Technology

RE:RE:New Press Release - Ventripoint Updates Submission to U.S. Food and Drug Administration for its Next Generation, AI-powered Heart-scanning TechnologyInteresting & see on post Ventripoint yesterday and see see like this Dr.Gregory James Skinner & Dario Freitas -Gregory James Skinner Hors rseau·Consultant Paediatric Cardiologist and Deputy Clinical Director - Women & Children’s Services
-Dario Freitas Lead Clinical Scientist for the ACHD Echocardiography service | Guy's and St Thomas' NHS Foundation Trust
We are excited to announce that we have submitted an update to the FDA in support of VMS+ 4.0, our most advanced product.

VMS+ 4.0 delivers two significant enhancements to improve clinical workflow
+ AI-assisted echo image analysis
+ Simplified sensor pairing.

Our thanks to Avania for their help and support!

VMS+ 4.0 has already received regulatory clearance in Canada, the UK and Europe.

AI echo VMS+

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities